CXCR4 and adrenal cortex carcinoma: As the CXCR4-specific tracer CPCR4 can be labeled with Lutetium-177 (53) and Yttrium-90 (54), endoradiotherapy of ACC may emerge as a future treatment option for patients with ACC.